Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA is the hereditary material in humans and almost all other organisms. Radiation, such as beta particles emitted by Yttrium-90, can induce various types of DNA damage, including single-strand breaks (SSBs), double-strand breaks (DSBs), base modifications, and clustered damages. These damages can lead to cell death, genomic instability, and mutations, making DNA a key target in cancer therapy. The effectiveness of Yttrium-90 is underpinned by its ability to cause irreparable DNA damage leading to cell death in targeted tumors. The cell death occurs either directly, or indirectly via ROS production. Repair pathways such as NHEJ and HRR are activated in response to radiation induced DNA damage.
Direct DNA damage (strand breaks, base modifications), indirect DNA damage via ROS generation
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA (Deoxyribonucleic Acid) (DNA).